Physician profile
Christopher Cole Laganke
NPI 1811931546
$710,611.54
in general payments reported to CMS, 2019-2025
79 companies · $106K in 2025
The $106K reported for 2025 was more than what 98% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $161K · 2020: $66K · 2021: $65K · 2022: $84K · 2023: $105K · 2024: $124K · 2025: $106K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $211K · Consulting Fee: $89K · Travel and Lodging: $18K · Food and Beverage: $16K · Honoraria: $400 · Education: $41.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $211,010.00 |
| Consulting Fee | $89,024.12 |
| Travel and Lodging | $18,316.01 |
| Food and Beverage | $15,608.96 |
| Honoraria | $400.00 |
| Education | $41.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $195,595.65 | 2019-2025 | Mavenclad, Mavenclad, Evobrutinib |
| Biogen, INC. | $168,542.41 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Genzyme Corporation | $60,189.73 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $42,970.89 | 2019-2021 | |
| Ares Trading Sa | $40,623.57 | 2024 | |
| Tg Therapeutics, INC. | $38,364.37 | 2022-2025 | Briumvi |
| Genentech USA, INC. | $32,057.53 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Celgene Corporation | $20,872.57 | 2020-2025 | Zeposia |
| Novartis Pharmaceuticals Corporation | $20,421.12 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $19,054.07 | 2021-2025 | Zeposia |
| Abbvie INC. | $12,117.95 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $11,750.23 | 2020-2025 | Acthar |
| Janssen Pharmaceuticals, INC | $8,693.26 | 2021-2024 | Ponvory, Spravato |
| Alexion Pharmaceuticals, INC. | $7,651.56 | 2019-2025 | Ultomiris, Soliris |
| Mallinckrodt Enterprises LLC | $7,626.40 | 2019 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $6,834.15 | 2019-2021 | |
| Ucb, INC. | $2,898.92 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Biohaven Pharmaceutical Holding Company Ltd. | $2,494.62 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $1,856.19 | 2021 | |
| Amgen INC. | $961.08 | 2019-2025 | Uplizna |
| Horizon Therapeutics Plc | $665.65 | 2022-2023 | Uplizna |
| Acorda Therapeutics, INC | $599.78 | 2019-2024 | Inbrija, Ampyra |
| Eisai INC. | $599.37 | 2019-2025 | |
| Argenx US, INC. | $584.48 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Lilly USA, LLC | $406.12 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Neurelis, INC. | $397.04 | 2021-2025 | Valtoco |
| Corium, LLC | $379.16 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $331.30 | 2023-2025 | Sunosi, Symbravo, Auvelity |
| Teva Pharmaceuticals USA, INC. | $320.17 | 2019-2023 | Austedo |
| Csl Behring | $304.54 | 2020-2025 | Hizentra |
| Takeda Pharmaceuticals U.S.A., INC. | $289.07 | 2019-2025 | Hyqvia |
| Adamas Pharmaceuticals, INC. | $229.13 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $201.28 | 2023-2024 | Ingrezza, Ongentys |
| Banner Life Sciences, LLC | $192.17 | 2022-2023 | |
| Ipsen Biopharmaceuticals, INC | $191.58 | 2019-2022 | |
| Scilex Pharmaceuticals INC. | $185.54 | 2019-2025 | |
| Genentech, INC. | $183.48 | 2022 | |
| Mdd US Operations, LLC | $178.31 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Supernus Pharmaceuticals, INC. | $173.05 | 2020-2023 | Qelbree |
| Grifols USA, LLC | $168.99 | 2019-2024 | Gamunex-C |
| Arbor Pharmaceuticals, INC. | $157.95 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $148.78 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $146.48 | 2020-2023 | Xtampza |
| Avanir Pharmaceuticals, INC. | $145.98 | 2019-2021 | |
| Cycle Pharmaceuticals INC | $145.67 | 2024-2025 | Tascenso Odt, Bafiertam |
| Catalyst Pharmaceuticals, INC. | $140.51 | 2021-2025 | Fycompa |
| Pfizer INC. | $135.28 | 2022-2025 | |
| Sk Life Science, INC. | $124.01 | 2021-2025 | |
| Jazz Pharmaceuticals INC. | $120.86 | 2019-2025 | Epidiolex |
| Harmony Biosciences LLC | $112.01 | 2022-2025 | Wakix |
| Octapharma USA, INC. | $104.14 | 2024-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Kyowa Kirin, INC. | $95.61 | 2020-2023 | Nourianz |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $86.98 | 2021 | |
| Merz Pharmaceuticals, LLC | $75.41 | 2024-2025 | Xeomin |
| Axonics, INC. | $72.23 | 2021 | |
| Vanda Pharmaceuticals INC. | $66.68 | 2024-2025 | Ponvory, Fanapt |
| Acadia Pharmaceuticals INC | $64.55 | 2025 | Nuplazid |
| Boston Scientific Corporation | $59.63 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Neos Therapeutics, Lp | $57.34 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $44.28 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $34.68 | 2019 | |
| Ironwood Pharmaceuticals, INC | $29.82 | 2019-2020 | |
| Tanabe Pharma America, INC. | $26.21 | 2019-2025 | Radicava |
| Strongbridge US INC. | $26.10 | 2019-2020 | |
| Bausch Health US, LLC | $24.96 | 2024 | Aplenzin, Wellbutrin |
| Greenwich Biosciences, INC. | $24.82 | 2019 | |
| Lundbeck LLC | $22.79 | 2023 | Vyepti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.30 | 2019 | |
| Atland Pharmaceuticals, LLC | $20.12 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Aquestive Therapeutics, INC. | $19.90 | 2019 | |
| Noven Therapeutics, LLC | $17.44 | 2024 | Xelstrym |
| Medtronic, INC. | $16.73 | 2023 | Synchromedii |
| Livanova USA, INC. | $16.51 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Idorsia Pharmaceuticals US INC | $12.76 | 2023 | Quviviq |
| Daiichi Sankyo INC. | $12.46 | 2019 | |
| Galt Pharmaceuticals, LLC | $4.07 | 2023 | Oravig, Orphengesic Forte |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$12,198.81 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Laganke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.